Clinical Trial Update: Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating MAGE-3.A1 peptide vaccine with CpG 7909 adjuvant in metastatic melanoma has been terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• CPG 7909 (CpG 7909)
• MAGE-3.A1 peptide (MAGE-3.A1 peptide)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Malignant Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-07-21